Lexaria Bio Science working with frontline companies to battle COVID-19

viewLexaria Bioscience Corp.

Lexaria Bioscience (CSE:LXX-OTCQX: LXRP) CEO Chris Bunka joined Steve Darling from Proactive in Vancouver to discuss the company commencing a program, in collaboration with leading laboratories in Canada and the U.S. to study the benefits of DehydraTECH  in the fight against coronavirus disease COVID-19.

Bunka telling Proactive about that technology and why it may be effective, in the way it delivers fat-soluble drugs into the bloodstream.


Market: CSE
Market Cap: $33.9 m

View company profile

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Lexaria Bioscience Corp. named herein, including the promotion by the Company of Lexaria Bioscience Corp. in any Content on the Site, the...


Deep dive


Lexaria Bioscience is seeing increased demand for its DehydraTECH drug...

Most read

Buds & Duds: Cannabis stocks hold steady; Lexaria rises on amended agreement...

The North American Marijuana Index, which tracks the top cannabis stocks in the US and Canada, inched 0.2% higher at 122.9 points. Elsewhere, the OTCQX Cannabis index lost 0.2% to 489.3 points. Buds today are Lexaria Bioscience Corp (CSE:LXX) (OTCMKTS:LXRP), Curaleaf Holdings Inc...

on 01/22/2020

2 min read

Lexaria Bioscience widens scope of pharmaceutical ...
Lexaria Bioscience initiates coronavirus drug deli...